Abstract
In our study, we aimed to investigate the relationship between anti-müllerian hormone (AMH) and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score, which are known to be increased in patients with polycystic ovary syndrome (PCOS), and morning blood pressure surge (MBPS), and whether these measurements are a marker for early cardiovascular disease risk in patients with PCOS. Forty patients aged between 18 and 65 years with hypertension (HT) and PCOS, 40 patients with HT but without PCOS, and 40 people representing the healthy control group were included in our prospective, cross-sectional study. All patients underwent ambulatory blood pressure measurement for 24 hours and MBPS was calculated. The study groups were divided into 3 groups as healthy control group (group 1), patient group with HT without PCOS (group 2), and patient group with HT and PCOS (group 3). MBPS was found to be statistically significantly higher in group 3. In linear regression analysis, AMH and HOMA-IR levels were found to be independently associated with MBPS. In patients with PCOS, AMH, and HOMA-IR levels were significantly higher in the group with MBPS > 25 mm Hg. Early diagnosis and treatment of PCOS and accompanying comorbidities can halt the progression of cardiac disorders and reduce cardiovascular mortality and morbidity. AMH level, HOMA-IR score, and MBPS measurement can be used in early detection and prediction of cardiovascular disease in PCOS patients.